Name: Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.
Uploaded: 2023-12-13T07:25:14.939101+00:00
Duration: 467 s
Channel: Vox Markets
Description: Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/780/006780/video_FwLV5cO.mp4#t=41

Vox Markets

Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.

How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk

A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.

Mo Khan, chief executive of hVivo, tells Vox about a new £17m human challenge contract with an existing customer, and the progress the company’s made to deliver better than expected results this year.

0:41 Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.
2:35 How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk
5:32 A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.

Mo Khan, chief executive of hVivo, tells Vox about a new £17m human challenge contract with an existing customer, and the progress the company’s made to deliver better than expected results this year.0:41 Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025. 2:35 How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk 5:32 A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/780/006780/video_FwLV5cO.mp4